NasdaqGS:DFTXPharmaceuticals
Is It Too Late To Consider Definium Therapeutics (DFTX) After Its 213% One Year Surge?
If you are wondering whether Definium Therapeutics at around US$21.70 still offers value after a strong run, this review of its pricing is designed to help you frame that question clearly.
The stock has delivered a 59.1% return year to date and a 213.1% return over the last year, with shorter term moves including a 5.3% return over 30 days and a 3.5% decline over the past week.
These swings sit against a longer track record where the 3 year return is very large at roughly 7x, while the 5...